Zhejiang Hisun, Pfizer to Form $295 Million Drug Venture

Zhejiang Hisun Pharmaceutical Co. and Pfizer Inc. (PFE) agreed to form a $295 million venture to develop expired-patent drugs, according to a statement from the Chinese company to Shanghai’s stock exchange yesterday after markets closed.

To contact the editor responsible for this story: Gregory Turk at gturk2@bloomberg.net

Press spacebar to pause and continue. Press esc to stop.

Bloomberg reserves the right to remove comments but is under no obligation to do so, or to explain individual moderation decisions.

Please enable JavaScript to view the comments powered by Disqus.